MediWound Ltd.
MDWD
Positions held
Your positionsMDWD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $160.35M | Enterprise value | $133.61M | Trailing P/E | — | Forward P/E | -5.42 |
| PEG | — | Price / book | 4.50 | Beta | 0.09 | Dividend yield | 0.00% |
| Revenue growth | -45.8% | Earnings growth | — | Gross margin | 15.5% | Operating margin | -3.1% |
| Profit margin | -1.7% | ROE | -72.4% | ROA | -28.6% | Debt / equity | 0.24 |
| Current ratio | 2.32 | Free cash flow | -$29.05M | Analyst recommendation | strong_buy | Mean target | $30.67 |
| 52w high | $20.03 | 52w low | $12.42 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1M | $1.5M | $1.9M | $5.4M | $5.7M | — |
| Op margin | -305.9% | -541.0% | -418.5% | -120.2% | -100.1% | — |
| Net income | -$7.4M | -$3.0M | -$7.2M | -$2.7M | -$13.3M | — |
| Gross margin | 10.9% | 21.9% | 14.9% | 16.5% | 23.5% | — |
| Gross profit | $0.3M | $0.3M | $0.3M | $0.9M | $1.3M | — |
| Operating income | -$9.5M | -$8.0M | -$7.8M | -$6.5M | -$5.7M | — |
- Revenue +110% vs prior quarter ($3.1M vs $1.5M).
- Gross margin 10.9% (was 21.9% prior quarter).
- Operating margin expanded to -305.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.0M | $20.2M | $18.7M | $26.5M | — |
| Op margin | -149.1% | -95.8% | -83.0% | -28.9% | — |
| Net income | -$23.9M | -$30.2M | -$6.7M | -$19.6M | — |
| Gross margin | 19.2% | 13.0% | 19.1% | 49.7% | — |
| Gross profit | $3.3M | $2.6M | $3.6M | $13.2M | — |
| Operating income | -$25.3M | -$19.4M | -$15.5M | -$7.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
2026-09-02 · MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-20 · MediWound (MDWD) Q2 2026 Earnings Call Transcript
2026-08-14 · Oppenheimer Adjusts Price Target on MediWound to $30 From $32, Keeps Outperform Rating
2026-08-14 · MediWound Ltd. Q2 2026 Earnings Call Summary
2026-08-13 · MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...
2026-08-13 · MediWound Q2 Earnings Call Highlights
2026-08-13 · MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 · MediWound: Q2 Earnings Snapshot
2026-08-13 · MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-10 · ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns